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Abstract Rationale: LY354740 is a recently developed
metabotropic glutamatergic receptor 2 and 3 (mGluR2/3)
agonist. A high density of mGluR2 has been reported in
terminal fields of the perforant path in rodents and humans,
suggesting its involvement in cognitive functions medi-
ated by the temporal lobe, including memory. A small
number of in vivo studies in rodents have assessed the
effects of LY354740 on memory tasks, reporting the in-
duction of impaired memory for spatial orientation in a
water maze task and for delayed match and non-match to
position in an operant version of these tasks. Objective:
In the present primate study, we used radioautography to
describe the distribution and intensity of 3H-LY354740
binding in the hippocampal formation of the common
marmoset monkey (Callithrix jacchus) relative to the rat.
In the major, in vivo part of the study, the effects of sys-
temic LY354740 on computerized tasks of attention and
memory were investigated. Methods: Adult common
marmosets were trained to perform a five-choice serial
reaction time (5-CSRT) task and a concurrent delayed
match-to-position (CDMP) task from the Cambridge Neu-
ropsychological Automated test Battery (CANTAB). Filter
tests of LY354740 effects on motor dexterity and motiva-
tion for reward revealed high inter-individual variation in
sensitivity; therefore, on the 5-CSRT, subjects were tested at
a dose range of 3–10 mg/kg, and on the CDMP, subjects
were tested at 1–3 or 3–10 mg/kg. Results: Radioautog-
raphy revealed a relatively low level of 3H-LY354740
binding in the marmoset hippocampal formation compared
to the rat. Despite low binding, LY354740 reduced sus-
tained-attention accuracy in the 5-CSRT, and reduced
accuracy in two stages of the CDMP. Conclusions: The
current study provides novel evidence for the importance
of mGluR2/3 in the regulation of primate cognitive
functioning.
Keywords Metabotropic glutamatergic receptor .
LY354740 . Primate . Marmoset . CANTAB . Attention .
Working memory
Introduction
Glutamate receptors are classified into two different func-
tional groups: ionotropic receptors and metabotropic re-
ceptors. At least eight metabotropic glutamate receptors
(mGluRs; with splice variants) are described, subdivided
into three groups according to their primary structure,
second-messenger coupling, and pharmacology. Group I
receptors include mGluR1 and 5, group II mGluR2 and 3,
and group III mGluR 4, 6, 7 and 8 (Conn and Pin 1997).
mGluRs are considered to have a modulatory function and
therefore to constitute a pharmacological target for selec-
tive drugs with therapeutic potential (Conn and Pin 1997;
Holden 2003).
mGluR2 has a distinct distribution in the rodent brain. Of
particular interest is the high density of mGluR2 identified
in the perforant path, the main input projection between
entorhinal cortex and the hippocampal formation (Higgins
et al. 2004; Neki et al. 1996; Ohishi et al. 1998; Shigemoto
et al. 1997). The entorhinal cortex receives input from
multiple neocortical association areas and represents an
important convergent site for information into the hippo-
campus (Eichenbaum 2000; Squire and Knowlton 1995).
However, the potential role of mGluR2 in memory reg-
ulation has received little attention to date.
Recently, pharmacological agents acting at specific
mGluR subtypes have been developed, and these include
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the group II-selective agonist LY354740 and antagonist
LY341495 (Schoepp et al. 1999). Group II mGluR agonists
have been reported to have neuroprotective, anxiolytic/anti-
panic and anti-Parkinsonism properties, as well as anti-
psychotic potential (Holden 2003; Pilc 2003; Schoepp et al.
2003). Since LY354740 binds to both mGluR2 and 3, it is
likely that some of its effects are mediated more specifically
by the activation of one or other of these two receptor
subtypes. Such functional specificity is also suggested by
the cell types expressing these two receptor subtypes, with
mGluR2 expressed primarily in neurons and mGluR3 pri-
marily in glial cells (Ohishi et al. 1993a,b, 1994; Tanabe et
al. 1993) Although mGluR2/3 agonists have been consid-
ered as targets with respect to a broad range of psychiatric
and neurodegenerative disorders, studies of the effects of
mGluR2/3 activation on cognitive functions have been
confined to a small number of rodent studies. LY354740 (1–
10 mg/kg) induced a delay-dependent performance deficit
in a T-maze task (Aultman and Moghaddam 2001), sup-
porting a role of mGluR2/3 in working memory, and also
induced working memory deficits in operant versions of
both delayed match and delayed non-match to position (D
(N)MP) tasks (Higgins et al. 2004). The latter study also
reported a deficit in spatial learning in a water maze task
with LY354740 (10 mg/kg, i.p.) and enhanced acquisition
in the water maze with the group II antagonist LY341495 (1
mg/kg, i.p). These findings provide evidence that group II
receptors can have an important role in learning and mem-
ory in rodents.
In a previous study (Spinelli et al. 2004), we demonstrat-
ed that a New World primate, the common marmoset
monkey (Callithrix jacchus), can perform the five-choice
serial reaction time (5-CSRT) task and a concurrent delayed
match to position (CDMP) task, from the CAmbridge
Neuropsychological Test Automated Battery (CANTAB;
Cambridge Cognition Ltd., Cambridge, UK), a computer-
ized battery of neuropsychological tasks presented as icons
on a touch-sensitive computer screen. The 5-CSRT task has
been used widely to assess visual attention in rodents (Carli
et al. 1983; Robbins 2002) and, in the case of the CANTAB
version, humans and rhesus macaques (Sahakian and Coull
1993; Weed et al. 1999). The CDMP task, comprising two
interpolated delayed match to position tasks, exhibits
similarities with the operant DMP task for rodents (Dunnett
1985, 1993), and also with CANTAB memory tasks used
widely in humans, including the delayed match to sample,
spatial recognition, and visuo-spatial paired associates
learning memory tasks (Robbins et al. 1997). We recently
demonstrated that the performance ofmarmoset monkeys in
the 5-CSRT and CDMP tasks is sensitive to pharmacolog-
ical manipulation of the cholinergic system, using nicotine
and scopolamine (Spinelli 2004).
The aims of the present common marmoset study were
to describe the distribution and abundance of mGluR2 and
3 in the temporal lobe of the adult brain using 3H-DCG-IV
and 3H-LY354740-based radioautography, and to investi-
gate the effects of LY354740 on attention and memory
using the CANTAB 5-CSRT and CDMP tasks.
Materials and methods
All experimental procedures were conducted under permit
and in accordance with the Animal Protection Act (1978),
Switzerland.
[3H]LY354740 and [3H]DCG-IV binding to marmoset
tissue sections and brain membranes
Common marmosets, two male and two female, were
sedated using Saffan (alphaxalone/alphadolone, 10 mg/kg
i.m.) and sacrificed with an overdose of sodium pentobar-
bital. The brain was rapidly removed, frozen in isopentane
at −60°C and then stored at −80°C prior to sectioning.
Cryostat sections of 15 μm in the coronal plane through the
hippocampal formation were thaw-mounted onto gelatin-
coated slides. In addition, parasagittal and coronal sections
of Wistar rats were also prepared. The rats were sacrificed
by decapitation under anesthesia with halothane, and then
the brain was rapidly removed, frozen in dry ice and then
stored at −80°C. Parasagittal cryostat sections (12 μm)
were thaw-mounted on pre-cleaned slides and stored at
−20°C until use. The brains of two adult female marmosets
were used for the preparation of membranes. Blocked tis-
sue from the prefrontal cortex, striatum, hippocampus,
temporal cortex and cerebellum was stored at −80°C prior
to preparation. Brain tissue from Wistar rats was used as
reference for binding studies. Methodological differences
in the processing of marmoset and rat brains reflect the
histology protocols of the Swiss Federal Institute of Tech-
nology and Hoffmann La Roche laboratories, respectively.
Quantitative receptor radioautography with [3H]LY35
4740 and [3H]DCG-IV was performed as described in
Higgins et al. (2004). Membrane binding studies were
performed as described in Schaffhauser et al. (1998) and
Mutel et al. (1998), with protein content measured using the
bicinchoninic acid method.
Western blot analysis of mGluR2/3 expression
in the marmoset brain
Two polyclonal antibodies were used to detect mGluR2
and 3 gene products in the marmoset brain (human and rat
mGluR2 are 97% identical at the amino acid level). Mem-
branes were distributed in aliquots containing 20 μg pro-
tein in assay buffer with protease inhibitors. The aliquot
was thawed and centrifuged at 13,000 rpm for 20 min at
4°C. The pellet was resuspended in 40 μl Laemmli buffer
(with or without 20mMDTT), heated for 5 min at 50°C and
loaded on a 7.5% polyacrylamide gel. The transfer on to
nitrocellulose membranes (Bio-Rad) was carried out in 25
mM TRIS, 192 mM glycine and 20% methanol using the
Semidry Transfer in Trans blot SD transfer Cell (Bio-Rad)
(45 min, 20 V). After rinsing in TBS Tween, blocking was
carried out in 1%BSA/TBST for 1 h. The selective mGluR2
rabbit polyclonal antibody (Upstate Biotechnology, Lake
Placid, NY, USA; 1:2,000, epitope corresponding to AA
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829–845 of rat mGluR2), and a rabbit polyclonal mGluR2/3
antibody (Calbiochem, 1:1,000, raised against the carboxy-
terminus peptide NGREVVDSTTSSL) were used as prima-
ry antibodies. After overnight incubation at 4°C, the filter
was incubated (1 h; RT) with a secondary antibody, anti-
POD (1:10,000 in 0.5% milk/TBST) or with Alexa Fluor
680 goat anti-rabbit antibody (1:20,000 in PBST for
fluorescent detection; Molecular Probes, Eugene, OR,
USA). The detection system was either ECL Plus (Amers-
ham Biosciences) following manufacturer’s instructions, or
Odissey Scanner analysis for protein semi-quantification. In
the case of fluorescent staining, actin was also stained in the
same gel using a mouse anti-actin monoclonal antibody
(1:10,000) and the IRDye 800 anti-goat IgG (Rockland,
Gilbertville, PA).
Marmoset subjects and care
The behavioural study was conducted with 17 adult com-
mon marmosets (ten females and seven males), aged 2–12
years. Details of caging, maintenance and home-cage
behavioural training and testing are provided in Spinelli et
al. (2004). Eight subjects were allocated to the non-cog-
nitive tasks used to establish a dose range of LY354740
that did not impair motor dexterity or motivation. Two of
these subjects and a further nine subjects were studied in
either an attention task or a memory task. Training on
these cognitive tasks required several months. Five and six
subjects were trained to a level of stable accurate per-
formance on the attention and memory tasks, respectively.
We attempted to train several additional animals on these
tasks but they did not attain a stable level of above-chance
performance. Prior to the present study, the same mar-
mosets had been included in a pharmacological validation
of the cognitive tasks based on two reference cholinergic
drugs, scopolamine and nicotine (Spinelli 2004). These
validation studies were completed 2 months prior to the
onset of the present study.
ORD task performed with the WGTA
The object reaching with detour (ORD) task was used to
establish the effects of LY354740 on motor capabilities
(Taylor et al. 1990), and was presented using a Wisconsin
General Test Apparatus (WGTA) [42 (L)×40 (W)×45 (H)
cm]. The ORD task required the marmoset to retrieve a
reward from within a transparent Plexiglas cube that
measured 4×4×4 cm and was open on one side. Pieces of
dry biscuit soaked briefly in banana-flavored milkshake
were used as reward. The cube was presented with the open
side on the left, right or front of the monkey. Two black
diagonal lines were drawn on each side and the back of the
cube; therefore, subjects could see the reward placed inside
the cube and also had visual cues (Hauser 1999). During test
sessions of a maximum of 24 trials, the reward was placed
in the centre of the cube and the orientation of the open
side was to the front, left, or right relative to the subject,
according to a pseudo-random schedule, but with an
equal number of each trial type. The following measures
were calculated: number of trials per session; number of
successful responses, i.e. reward retrieved at the first at-
tempt; number of impulsive responses, i.e. at the first at-
tempt the subject reaches to the front when the open side
was on the left or right; number of perseverative responses,
i.e. at the first attempt the subject reaches to a wrong side
on the left or right, where this side was correct on the
previous trial. After several test sessions, marmosets at-
tained a stable level of performance of ca. 80% success-
ful responses. Against this background, the effects of
LY354740 were assessed, with the major aims of detecting
doses that did or did not (1) impair dexterity, defined as
the first response on a trial being to the open side of the
cube but the first retrieval attempt unsuccessful, or (2)
reduce motivation, defined as a reduced number of trials
completed.
CANTAB: apparatus, training and tasks
The Monkey CANTAB Testing Station (marmoset set-up,
Cambridge Cognition Ltd., Cambridge, UK) and the
training procedures used for home cage CANTAB testing
are described extensively in Spinelli et al. (2004).
Progressive ratio schedule of reinforcement
In four subjects, effects of LY354740 on feeding motiva-
tion were assessed using the progressive ratio (PR)
schedule of reinforcement. The major measures of moti-
vation were the total numbers of responses made and
reinforcements obtained (Spinelli et al. 2004).
Five-choice serial reaction time task
The 5-CSRT task was applied in five subjects in order to
assess the effects of LY354740 on divided and sustained
attention (Spinelli et al. 2004; Taffe et al. 2002). The
duration for which the lever had to be depressed before
the blue stimulus appeared was set to a range of 0.1–1.0 s.
The dependent measures studied were: total number of
trials performed; percent correct responses/total trials; per-
cent accuracy, i.e. percent correct responses/total (correct+
incorrect) responses; percent omissions (trials where a
stimulus was presented but the subject did not touch the
screen); percent release lever too soon (subject did not
depress the lever until the blue target stimulus appeared on
the screen); lever release latency (time taken to release the
lever after the stimulus appeared on the screen, when
response was correct); and movement time (time from lever
release until screen touching, when response was correct).
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Concurrent delayed match to position task
The CDMP task, studied here in terms of LY354730’s
effects in six subjects, was derived from the monkey
CANTAB visuo-spatial paired associates learning (vsPAL)
task (Spinelli et al. 2004; Taffe et al. 2002). The design of
the task is given in Fig. 1.
LY354740 and behaviour
The compound (1S,2S,5R,6S)-2-amino-bicyclo[3.1.0]hex-
ane-2,6-dicarboxylic acid (LY354740; synthesized at F.
Hoffmann-La Roche, Basel, Switzerland), was dissolved
in 0.9% NaCl solution and pH was adjusted to ≈7.0 with
sodium hydroxide. Doses were injected i.p. in a volume of
0.6 ml/kg and with a pre-treatment time of 40 min. Drug
doses of 1–5 mg/kg were counterbalanced in each ex-
periment, whereas higher doses (7.5 and 10 mg/kg) were
injected in ascending order and only in cases where sub-
jects had not exhibited specific side effects at a lower dose.
Animals were typically tested daily from Monday to Fri-
day, with injections occurring twice per week, saline usu-
ally on Tuesday or Wednesday and LY354740 on Thursday
or Friday; LY354740 testing was performed only if the
saline session performance was similar to baseline per-
formance in that week, otherwise the saline session was
repeated.
Experiment 1: ORD task and PR schedule
The effects of LY354740 at 1.0–7.5 mg/kg i.p. on motor
performance and motivation were assessed using the ORD
task and PR schedule, and results indicated marked in-
dividual differences in LY354740 sensitivity. However, 3
mg/kg was well-tolerated by most of the eight subjects,
and this dose was used for cognitive task pre-injections.
One week prior to the beginning of cognitive testing (Ex-
periments 2 and 3), subjects were pre-exposed for 2 con-
secutive days to 3 mg/kg LY354740; and observed for
behavioural effects. According to reactions to pre-injec-
tions, “high sensitivity” and “low sensitivity” subjects
were identified. The high-sensitivity group was tested at 1,
2 and 3 mg/kg and the low-sensitivity group at 3 and 5
mg/kg. In the latter group, if LY354740 did not affect task
performance, doses of 7.5 and finally 10 mg/kg were ad-
ministered. The maximum dose of 10 mg/kg was based on
rat findings of reduced spontaneous locomotor activity and
operant chain pulling behaviour at this dose (unpublished
data).
Experiment 2: 5-CSRT task
All five subjects were in the LY354740 low-sensitivity
group and tested with 3 and 5 mg/kg LY354740. When
injected with 5 mg/kg, two animals did not complete all
trials and showed considerable side effects. The other three
monkeys were also tested at 7.5 and 10 mg/kg. In Ex-
periment 2a, test conditions were a maximum session
length of 20 min or a maximum number of 45 trials, with
a random-balanced design of three stimulus display dura-
tions (0.1, 0.5 and 1.0 s) and 15 trials per duration. For each
subject, the highest dose that did not induce a reduction in
the number of trials completed was repeated in Experiment
2b. Since in Experiment 2a there was no effect of
LY354740 on accuracy, the attentional load of the task
was increased in Experiment 2b by using two SDs, 0.1 and
0.5 s, and increasing the number of trials to 60. Test
conditions were a maximum session length of 25 min or 60
trials, with a random-balanced design of 30 trials per SD.
Memory
delay:
0.5 s
Sample
delay:
0.1 s
Choice delay:
Reinforcement time 8s
or punishment time 3s
First choice stage
Sample stimulus # 1
50%
Second choice stage
First choice stage
Sample stimulus # 2
50%
Second choice stage
Sample stage #1 Sample stage #2
+
Choice delay:
Reinforcement time 8s
or punishment time 3s
_ +
_
+
_ +
_
Fig. 1 Schematic of the test sequence in the concurrent delayed
match-to-position task. Each trial comprises either a sequence of
stimulus presentation in which the first choice stage uses sample
stimulus/position #1 such that the subject has to shift between
stimuli and positions (upper scheme), or a sequence of stimulus
presentation in which the first choice stage uses sample stimulus/
position #2 and therefore does not require a shift (lower scheme).
Each stimulus disappears immediately after responding. For both
sequences, a correct choice at choice stage 1 results in 8-s rein-
forcement followed by a return to the screen for choice stage 2,
whilst an incorrect choice at choice stage 1 results in choice stage 2
following a 3-s punishment time out. It should be noted that mar-
mosets did not need to discriminate between stimuli #1 and #2 in
order to make correct responses. This was due to the non-overlap
between the sample and distracter positions used for stimulus #1 and
stimulus #2 within each trial
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Experiment 3: CDMP task
The maximum session length was 25 min or 35 trials. Two
of six subjects performed consistently less than 35 trials
and therefore their maximum number of trials was reduced
to 30. Three of six subjects were of high sensitivity and
tested with 1, 2 and 3 mg/kg (doses counterbalanced) and
three were of low sensitivity and tested with 3 and 5 mg/kg,
doses counterbalanced, and then at 7.5 and 10 mg/kg.
LY354740 pharmacokinetics using HPLC
After cognitive testing, in an attempt to gain insight into
observed individual differences in LY354740 sensitivity,
plasma concentrations were measured in low- and high-
sensitivity subjects. In five marmosets, a blood sample (0.3
ml from the femoral vein) was withdrawn into an EDTA-
primed syringe. LY354740 was administered at 2–3 mg/kg
(n=3 high-sensitivity subjects) or 5–10 mg/kg (n=2 low-
sensitivity subjects). Further blood samples were then
withdrawn at 30 min, 60 min and 24 h post-treatment.
Bloods were placed immediately on ice and then cen-
trifuged, and plasma was stored at −80°C prior to analysis.
Plasma samples were treated with 3 volumes of methanol
also containing an internal standard. The samples were
centrifuged (3,500 g, 20 min 10°C) and the supernatant
injected directly onto a high pressure liquid chromatography
(HPLC) system. HPLC analysis was conducted on a normal
phase column (GROM Spherisorb-CN 125×2 mm) at 40°C
using a polarity gradient (phase A methanol and phase B
methanol/ formic acid 1% 20:80) with a flow rate of 300 μl/
min. A PE-Sciex API-2000MS/MS mass spectrometer was
used for detection (ion source: turbo ion spray ionisation).
Data analysis
Scores on the ORD task and PR schedule were analysed
using one-way analysis of variance (ANOVA), with
LY354740 dose as a within-subject factor. Performance
and latency scores on the 5-CSRT task were analysed using
a two-way ANOVAwith stimulus duration and LY354740
as within-subject factors. For Experiment 2b, data were
divided into two trial bins (1–30, 31–60) and analysed using
a nested three-way ANOVAwith within-subject factors of
SD, LY354740 and trial bins. Performance and latency
scores on the CDMP task were also analysed using a two-
way ANOVA with choice stage and LY354740 as within-
subject factors. Statistical significance was set at p<0.05,
and significant effects were analysed post-hoc using
Fisher’s protected least significant difference for pair-wise
comparisons or t-test based on the error term derived from
the appropriate overall ANOVA.
Results
mGluR2/3 radioautography and Western blot
The binding density of both [3H]LY354740 and [3H]DCG-
IV by marmoset tissue was considerably reduced relative
to that of rat tissue. Table 1 presents a comparison of the
binding densities of different brain regions in adult mar-
moset and adult rat, and the distribution and abundance of
total binding sites (>85% specific) is illustrated in Fig. 2.
In the rat, the highest level of binding was to be observed
in the lacunosum moleculare/perforant path of the hippo-
campal formation (Fig. 2a). In the marmoset there was
rarely the same high level of binding, and the lacunosum
moleculare was barely distinguishable from the surround-
ing tissue, other than by histology (Fig. 2b). Marmoset
membrane binding studies using homogenate from dif-
ferent brain areas showed the presence of specific binding
for [3H]LY354740 with a Kd of about 10 nM in hippo-
campus and 30 nM in striatum, using one-site model curve
fitting. Calculated Bmax values were always below 300
fmol/mg of protein with the lowest specific binding in
cerebellum. The relatively low expression of mGluR2 and
mGluR3 in marmoset versus rat cortical regions was also
confirmed by the Western blot studies (data not shown).
Neuropsychological tasks
Experiment 1: ORD task and PR schedule
Table 2 presents the percent trials completed in the ORD
task. One subject already exhibited a marked reduction in
trials completed at 1 mg/kg, as well as gastrointestinal side
effects at 3 mg/kg, and therefore was not injected with 5mg/
kg. Three animals completed at least 70% of trials at all
doses; in these subjects, for percent successful responses,
there was no significant effect of LY354740, with per-
formance consistent at a mean of 75–80% at each dose. In
the PR schedule, LY354740 at 1 or 3 mg/kg did not exert a
significant effect on the number of responses performed or
reinforcements obtained, e.g. total responses were: SAL
Table 1 [3H]LY354740 and
[3H]DCG-IV binding (fmol/mg
protein) by marmoset and rat
brain
Values are mean±SEM based on
N=3–4 subjects, and two to four
sections per subject
Region [3H]LY354740 [3H]DCG-IV
Rat Marmoset Rat Marmoset
Lacunosum moleculare 7,507±1,181 1,382±227 4,757±408 464±93
Dentate gyrus 4,594±820 1,560±343 2,411±309 605±153
CA1 1,062±236 1,144±377 432±24 128±49
Caudate putamen 3,249±502 1,537±251 2,530±527 524±53
Cortex 4,795±653 1,310±199 3,086±147 384±49
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147±41; 1 mg/kg 136±24; 3 mg/kg 156±27. Two subjects
that did not exhibit behavioural side effects at 3 mg/kg were
treated with up to 7.5 mg/kg and at these doses also did not
exhibit altered motivation, e.g. total responses at 7.5 mg/kg:
140±3.
Therefore, Experiment 1 identified high individual var-
iability in LY354740 effects on motivation. The dose of 3
mg/kg was well tolerated by six of eight subjects tested and
this was confirmed by qualitative behavioural observations
conducted across 60 min post-injection. The side effects
observedwith LY354740were increased frequency of some
natural marmoset behaviours, e.g. head rubbing on branch-
es, head and body shaking, and repeated scratching of body
and tail; tail swirling, which is not in the marmoset’s natural
repertoire, was also observed. The dose of 3 mg/kg was
selected for pre-treatment prior to cognitive testing, and
behavioural reaction to two such pre-treatments provided
the main indication of individual sensitivity. High-sensitive
subjects demonstrated high frequencies of head rubbing on
branches, shaking and scratching, while low-sensitive
subjects did not.
Experiment 2: 5-CSRT tasks
Five low-sensitive subjects were treated with 3 and 5 mg/kg
LY354740, and at 5 mg/kg two monkeys performed only
42% or 71% of trials and three performed all trials up to 10
mg/kg. With SDs of 0.1, 0.5 and 1.0 s and 45 trials/session
(Experiment 2a), ANOVA was conducted with two mar-
mosets at 3 mg/kg and three at 10 mg/kg. There was a
significant main effect of SD on accuracy [F(2,8)=16.12,
p<0.002] in the absence of a significant main effect of
LY354740. Fisher’s post-hoc analysis indicated that percent
accuracy was significantly reduced at SD 0.1 s (68±5) com-
pared to SD 0.5 (94±2; p<0.02) and 1.0 s (96±2; p<0.01). A
significant main effect of SD was also found on percent
correct responses/total responses [F(2,8)=7.92, p<0.02], with
Fisher’s post-hoc analysis indicating that percent correct
responses was significantly reduced at SD 0.1 s (53±4)
compared to SD 0.5 s (75±4; p<0.03) and 1.0 s (83±4;
p<0.005). With this same measure there was no main
effect of LY354740. There was a trend towards a signif-
icant decrease in lever release latency due to LY354740
[F(1,4)=6.64, p<0.07]. None of the other measures of the
task (omissions, release lever too soon, response latency)
was affected by SD (p>0.1) or LY354740 (p>0.1).
In Experiment 2b, the attentional load of the task was
increased by presenting 60 trials and employing SDs of
0.1 and 0.5 s. Under these task conditions, four marmosets
performed all trials across several sessions; one did not
and was subsequently excluded. Three animals were tested
at 10 mg/kg and one at 3 mg/kg (this latter subject per-
formed only 71% of 45 trials in Experiment 2a at 5 mg/kg).
For accuracy (Fig. 3a), there was a significant SD ×
LY354740 × trial-block interaction [F(1,3)=10.73, p<0.05],
and a significant SD × trials block interaction [F(1,3)= 32.55,
p<0.02], in addition to a main effect of LY354740 [F(1,3)=
43.44, p<0.008] and a main effect of SD [F(1,3)= 631.4,
p<0.0001]. Post-hoc t-comparisons indicated that LY354740
significantly reduced accuracy at SD 0.1 s during the second
block of trials (31–60) [t(3)=4.65, p<0.02], in the absence
of significant effects during the second block of trials
(31–60) at SD 0.5 s or during the first block of trials
(1–30) at either SD 0.1 or 0.5 s (Fig. 3a). For percent
correct responses/total trials, there was a significant main
effect of SD [F(1,3)=533.63, p< 0.0002], a significant main
effect of trial block [F(1,3)= 13.96, p<0.04], and a trend to a
significant main effect of LY354740 [F(1,3)=9.12, p<0.06].
These findings reflected the decrease in correct responses
at SD 0.1 s (55±5.1) versus 0.5 s (78±3.6), the decrease in
correct responses at trials 31–60 (61±6.2) versus 1–30 (72±
3.8), and the tendency for LY354740 to decrease correct
responses at trials 31–60 (SAL 71±6.3; LY 51±9.9). For omis-
sions, there was no significant effect involving LY354740,
but a significant trial-block main effect [F(1,3)=108.9,
Fig. 2 Representative autora-
diograms of [3H]LY354740
binding in the hippocampal
formation in a a rat parasagit-
tal section and b a marmoset
coronal section
Table 2 Effects of LY354740 (mg/kg) on motivation to perform the
ORD task
Subject Percent trials completed
Saline LY 1 LY 3 LY 5
Con 100.0 100.0 100.0 12.5
Ing 100.0 41.7 0.0 –
Lul 100.0 100.0 100.0 0.0
Dia 100.0 100.0 100.0 83.3
Dan 100.0 83.3 100.0 100.0
Ivo 100.0 83.3 70.8 100.0
The maximum number of trials per session was 24
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p<0.002], and a trend to a significant SD main effect
[F(1,3)=9.78, p<0.06] (Fig 3b). For lever release latency,
there was a significant main effect of LY354740 [F(1,3)=21.24,
p< 0.02] and a trend to a significant main effect of SD
[F(1,3)= 9.83, p<0.06] (Fig. 3c). Post-hoc t-comparison
showed that LY354740 induced a significant reduction in
lever release latency at SD 0.1 s [t(3)=3.66, p<0.05], and
tended to do so at SD 0.5 s [t(3)=2.75, p<0.1]. LY354740
did not significantly affect any other measure of the 5-CSRT
task.
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Fig. 3 Effect of LY354740
(3 or 10 mg/kg) on performance
(mean±SEM) of four marmosets
in the five-choice serial reaction
time task (stimulus durations =
0.1 and 0.5 s, trials = 60) as
measured in terms of a percent
accuracy, b percent omissions/
total trials, and c lever release
latency
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Fig. 4 Effects of LY354740 on
performance in the concurrent
delayed match-to-position task
in a high-sensitivity subjects
that received 1–3 mg/kg and
b low-sensitivity subjects that
received 3–7.5 mg/kg. Percent
correct responses (mean±SEM,
n=3) across the four possible
sample stimuli × choice stage
conditions are given. In the
main figure, the values at choice
stage 2 are based on the average
of both trial types, i.e. sample #1
presented at choice stage 1,
sample #2 presented at choice
stage 1, correct response at
choice stage 1. The inset figure
shows performance at choice
stage 2 based on the average of
both trial types, i.e. sample #1
presented at choice stage 1,
sample #2 presented at choice
stage 1, incorrect response at
choice stage 1
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Experiment 3: CDMP task
Of the six marmosets trained in the CDMP task, three were
high-sensitive and tested at 1, 2 and 3 mg/kg, and three
low-sensitive and tested at 3, 5, 7.5 mg/kg and two also at
10 mg/kg. Figure 4a presents the CDMP performance of
the high-sensitivity group: there was a significant main
effect of LY354740 on percent correct responses [F(3,6)=
24.9, p<0.0009], in the absence of an interaction with or
a main effect of stage. Fisher’s post-hoc analysis re-
vealed a dose-dependent effect of LY354740, with perfor-
mance at 3 mg/kg significantly reduced compared to
saline (p<0.0002), 1 mg/kg (p<0.0004) and 2 mg/kg (p<
0.002). For response latency, there was a significant main
effect of stage [F(2,4)=139.21, p<0.0002] in the absence of a
main effect of LY354740: first choice stage with sample
stimulus #1: 1,006±67 ms, first choice stage with sample
stimulus #2: 1,028±65 ms, second choice stage after 8 s
delay: 3,334±225 ms. For the low-sensitivity group, there
was a trend towards a significant main effect of LY354740
on percent correct responses [F(3,6)=4.12, p<0.07] in the
absence of a significant effect involving stage (Fig. 4b).
Doses of 3 and 5 mg/kg tended to decrease performance at
the first stage of the task, but this was not significant for any
single stage type. As for the high-sensitivity group, there
was a significant main effect of stage on response latency
[F(2,4)=21.44, p<0.008], in the absence of any significant
LY354740 effect: first choice stage with sample stimulus
#1: 1,095±153 ms, first choice stage sample with stimulus
#2: 806±46 ms, second choice stage after 8 s delay: 3,077
±259 ms. Although these three subjects performed sessions
at each of these doses, at 7.5 mg/kg one subject performed
only 25 of 35 trials.
An individual-specific dose analysis was performed that
included all six subjects, with the dose selected for each
subject being the highest at which it performed at least
80% of the trials; this yielded a dose range of 2–10 mg/kg
LY354740.Therewas a significantmain effect ofLY354740
on percent correct responses [F(1,5)=11.4, p< 0.02], and a
tendency for a LY35740 × stage interaction [F(2,10)=3.26,
p<0.09], in the absence of any significant effect involving
stage (Fig. 5). Post-hoc t-comparison revealed a significant
LY354740-induced performance impairment at the first
choice stage when sample stimulus was #1 [t(10)=2.8,
p<0.05] and when sample stimulus was #2 [t(10)=3.14,
p<0.05], and no effect of LY354740 at the second choice
stage after 8 s delay. Response latency was significantly
affected by stage [F(2,10)=56.4, p<0.001], in the absence of a
LY354740 effect: first choice stage with sample stimulus
#1: SAL 1,101±250 ms, LY354740 934±80 ms; first choice
stage sample with stimulus #2: SAL 852±58 ms, LY354740
952±62 ms; second choice stage after 8 s delay: SAL
3,208±457 ms, LY354740 3,168±227 ms.
Pharmacokinetics
Given the marked individual differences in LY354740
sensitivity, we investigated the existence of differences
in drug metabolism. Five subjects were administered
LY354740 at the maximum dose at which they had been
studied, and their plasma concentrations were monitored.
As given in Table 3, the plasma titres of LY354740 were
proportional to the dose injected at 30 min post-injection.
Comparing titres at 60 and 30 min post-injection, the rel-
ative decrease in the two low-sensitivity marmosets was
Sample 
stimulus
#1
Sample 
stimulus
#2
First choice 
correct
Delay 8s
First choice stage Second choice stage
50
60
70
80
90
100
%
 C
or
re
ct
 re
sp
on
se
s
SALINE
LY 2-10 mg/kg
p<0.05
p<0.05Fig. 5 Effects of LY354740
(2–10 mg/kg) in six marmosets
on the concurrent delayed
match-to-position task. Mean
±SEM percent correct responses
at choice stage 1 with sample
stimuli #1 and #2, and at choice
stage 2 when response at choice
stage 1 was correct and subjects
received 8 s reward. For each
subject, the dose selected for
this analysis was the highest at
which it performed 80–100% of
trials. The saline data were those
obtained in the same study week
as the selected LY354740 dose
data
Table 3 LY354740 plasma ti-
tres (ng/ml) in marmosets with
different behavioural sensitivity
Subject Task Sensitivity Dose (mg/kg) Time relative to i.p. injection
−1 min 30 min 60 min 24 h
Cat CDMP Low 5 <50 15,500 7,100 <50
Hel CDMP Low 10 <50 36,500 19,350 <50
Con CDMP High 2 <50 9,400 6,980 <50
Cas CDMP High 3 <50 9,870 4,470 <50
Ils 5-CSRT High 3 <50 8,600 10,800 <50
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greater than that in two of the three high-sensitivity mar-
mosets. This suggests that sensitivity differences could be
related in part to differences in the efficacy of LY354740
metabolism.
Discussion
To the best of our knowledge, this is the first study of the
effects of the mGluR2/3 agonist LY354740 on the per-
formance of cognitive tasks in a primate species, and also
the first description of mGluR2/3 ligand binding in the
hippocampal formation of a non-human primate species.
Using [3H]LY354740 and [3H]DCG-IV, mGlurR2/3
binding by the hippocampal formation, and in particular
the lacunosum moleculare, was low in the marmoset com-
pared to the rat; indeed, the marmoset appears to exhibit
low levels of hippocampal mGluR2/3 relative to both rat
and human (Blumcke et al. 1996; Crook et al. 2002; Lee et
al. 2004). Western blot studies, using prefrontal cortex
tissue, suggest that marmoset mGluR3 expression was
greater than that of mGluR2; despite this, it is unlikely that
low marmoset binding was due to exclusive mGluR3
binding. mGluR2 knock-out mice exhibit normal basal
synaptic transmission and are without cognitive impair-
ment relative to the wild-type in terms of water maze
spatial navigation (Higgins et al. 2004; Yokoi et al. 1996).
These results indicate that mGluR2 is non-essential in at
least some learning and memory tasks known to require
temporal lobe integrity (Eijkenboom et al. 2000; Gerlai
et al. 2002; Skelton and McNamara 1992). However, in
the present study and despite the low levels of mGluR2/3
binding to LY354740, this agonist exerted marked be-
havioural effects and impaired cognition at doses at and
below those demonstrated to impair cognition in rodent
species.
Establishing the appropriate dose range of LY354740
for application in cognitive tasks was achieved using the
ORD task to assess motor dexterity (Taylor et al. 1990)
and the PR schedule for appetitive motivation (Spinelli et
al. 2004). ORD and PR schedule performance and, in
addition, observations of general post-treatment behaviour,
each indicated marked individual differences in sensitivity
to LY354740. Since 3 mg/kg was generally well tolerated,
cognitive-task subjects were pre-treated with this dose.
Depending on their general behavioural reactions, the
subjects were categorized as either low or high LY354740-
sensitive. Pharmacokinetic analysis confirmed that LY354740
was circulating at the time of cognitive testing, and at
levels proportional to the amount of drug injected.
For the 5-CSRT task, when subjects were tested using
three SDs and 45 trials, LY354740 did not affect per-
formance on any measure. When the attentional load of the
task was increased by using SD of 0.1 and 0.5 s and
increasing the number of trials to 60, LY354740 impaired
accuracy, specifically at the shortest SD in the second
block of trials. This suggests that LY354740 impairs sus-
tained attention, with the effect becoming evident when a
short SD is used. This deficit in sustained attention was
obtained with three animals treated with 10 mg/kg and one
with 3 mg/kg of LY354740; the drug effect was similarly
severe in all subjects, suggesting that an appropriate dose
was selected for each animal. Another potential mediating
process other than impaired attention would be reduced
motivation, but three lines of evidence argue against this.
Firstly, animals performed all trials, and in a previous
study (Spinelli et al. 2004), we demonstrated that reduced
motivation is mainly manifested as a reduction in the
number of trials performed. Second, response omissions, a
measure considered to be a motivation index in the rodent
version of the 5-CSRT task (Robbins 2002), were not in-
creased. Finally, lever release latency was decreased by
LY354740, whereas an increase would be expected in the
case of reduced motivation.
In the CDMP task, in the high-sensitivity group
LY354740 impaired performance dose-dependently, sug-
gesting that this subgroup comprised marmosets with a
similar sensitivity to this mGluR2/3 agonist. In contrast, in
the low-sensitivity group impairments were individual-
specific. Because of the limited number of subjects in each
group, the most important findings were obtained with the
overall individual-specific dose analysis, which indicated
that LY354740 reduced CDMP performance. At the first
choice stage when the sample stimulus was #2, subjects
tended to show a LY354740-induced impairment. At this
stage, the delay between the sample stimulus and the
choice presentation is short (0.5 s memory delay+response
time) and the animal does not need to move to another
position to respond correctly. LY354740 impaired perfor-
mance at the first choice stage when the sample stimulus
was #1: the memory load of this stage of the task is also
low (0.1 s sample delay+response time to stimulus 2+0.5 s
memory delay+response time), but there is a high po-
tential for within-trial retroactive interference due to pre-
sentation and responding to sample stimulus #2 being
interpolated between presentation of and the position-
choice stage for sample stimulus #1. LY354740 did not
affect the performance at the second stage after 8 s of
reinforcement, when the interval between sample presen-
tation and choice stage is longest and the memory load of
the task is highest. The lack of effect of LY354740 at this
stage of the task suggests (1) that the mGluR2/3 agonist
did not specifically affect memory, and (2) that the ability
to process two spatial engrams concurrently was not im-
paired, given that this trial type always followed a correct
response at the first choice stage. Furthermore, this finding
also supports the interpretation that the impairments ob-
tained at the other stages of the task were not due to
reduced motivation or a general inability of the monkeys
to apply the matching rule that underlies each stage of the
task. Within-trial interference is likely to act at each
choice stage of the CDMP, but the lack of LY354740
effect at the second choice stage/8 s delay, even when the
sample stimulus was #1, rather suggests that it does not
impair the on-line holding of positional information but
increases interference of retrieval, and specifically at short
delays between sample stimuli and choice. An alternative
explanation is that LY354740 impairs inhibitory control,
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expressed as a higher tendency to switch towards a
“novel” position, such that inhibition deficits are likely to
be higher in the first choice stage given that the second
choice stage occurs immediately after the subject has
consumed reward. Indeed, a marked natural predisposition
to alternate position has been reported in marmoset
monkeys using a T-maze spatial delayed non-match to
sample task (Easton et al. 2003), and faster learning for
the non-matching rule has been reported in various species
including macaques (Mishkin and Delacour 1975). Inhi-
bition measures are also provided by the ORD task
(incorrect responses to the front side of the cube) and 5-
CSRT task (premature lever release), but neither of these
measures was affected by LY354740. However, the large
numbers of sessions performed may have reduced the
sensitivity of these measures to modulation by LY354740.
The current findings for the effects of LY354740 on the
CDMP task differ from similar studies in rodents. In rats, a
delay-dependent deficit induced by LY354740 has been
demonstrated in a T-maze task (Aultman and Moghaddam
2001) and in the operant version of the D(N)MP task
(Higgins et al. 2004), strongly suggesting that LY354740
induces a memory deficit. In mice, LY354740 has been
demonstrated to impair spatial navigationmemory using the
water maze (Higgins et al. 2004). Our results in marmoset
monkeys do no support a specific effect of LY354740 in
terms of mnemonic impairment in the CDMP task. This
discrepancy between species could clearly be related to the
differences described here in terms of the density/affinity of
mGluR2/3. In vitro and in vivo studies will need to be
performed in additional primate species in order to clarify
the rodent–primate comparison at neurobiological and
behavioural levels.
In conclusion, in this study we have been able to extend
previous works on mGluR2/3 regulation of rodent cogni-
tion by describing the effects of systemic LY354740 ad-
ministration on the performance of marmoset monkeys in
CANTAB cognitive tasks. In the 5-CSRT task, LY354740
impaired accuracy with respect to detecting brief visual
stimuli across a relatively large number of trials. In the
CDMP task, LY354740 impaired performance at two
stages of the task with low memory retention load but high
memory interference effect. Therefore, although the mar-
moset monkey may not be the species of choice given the
low level of specific binding for LY354740 in hippocam-
pus and cortex identified in this study, the overall findings
indicate clearly that even under conditions of low central
expression, mGluR2/3 are important regulators of primate
cognitive functions. Future studies in other non-human
primate species, such as macaque monkeys, may help to
clarify the role of these receptors and their relevance as a
pharmacological target for the treatment of cognitive
dysfunction, including that associated with neurodegener-
ative diseases.
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